Swedish Orphan Biovitrum AB (publ)
The answer first
Does Swedish Orphan Biovitrum beat the market?
Yes, Swedish Orphan Biovitrum has beaten the market over the last year.
The ranking · Quality, value and trend combined
Better than 68% of Nordic stocks
- Quality79
- Value22
- Trend79
No. 41 of 192 in healthcare
Expectations in the price
High expectations
For the share to return about 9% a year from today's price, the cash Swedish Orphan Biovitrum keeps must grow about 8% a year for 10 years.
Max for seven days
Follow Swedish Orphan Biovitrum with AuroraAurora lets you know at the next report. No card.
Both with dividends. Figures as of 20 November 2026. General analysis, not personal advice.
Follow your thesis
Ask Aurora about Swedish Orphan Biovitrum
Your first answer is free, no account needed.
Do you own Swedish Orphan Biovitrum, or are you thinking about it?
See it next to the rest of your portfolio, or build your first one with Swedish Orphan Biovitrum and a few more. Free, no card.
Super Stock+46.4%In short
- Swedish Orphan Biovitrum has risen 39.6% over the past year, including dividends.
- Overall, Swedish Orphan Biovitrum ranks better than 68% of Nordic stocks on quality, value and trend.
- The largest fall over the past three years was 28.8%. The price is 6.9% below its peak now.
What do analysts think of Swedish Orphan Biovitrum?
Quality, value and trend
Quality is about the company, value about the price you pay, and trend about the share price. Each pillar shows the numbers it is built on.
Quality, value and trend together. Better than 68% of Nordic stocks.
No. 41 of 192 in healthcare
High A solid company: it earns well on its money and has healthy finances.
No. 54 of 196 in healthcareTypical in healthcare: 64Typical in the Nordics: 50
- Debt to equityBorrowings divided by equity0.32
- Asset turnoverSales divided by everything the company owns0.37
- Return on equityProfit divided by equity+14.6%
- Cash conversionOperating cash flow divided by profit1.19
The ranking is built on equity ratio, ROA and how steadily profit grows.
Low High price: buyers pay a lot today, often because they expect growth.
No. 89 of 194 in healthcareTypical in healthcare: 19Typical in the Nordics: 50
- P/BPrice divided by equity3.5
- P/SPrice divided by sales5.0
- P/EPrice divided by earnings24.1
- P/CFPrice divided by operating cash flow20.3
The ranking is built on P/E, P/B and P/S.
High Tailwind in the share price: it has risen more than most over the last year.
No. 44 of 198 in healthcareTypical in healthcare: 33Typical in the Nordics: 50
- 3 months−1.2%
- 6 months+4.5%
- 9 months+13.2%
- 12 months+39.6%
The ranking is built on 3, 6 and 12–1 months.
Return and risk
Return with dividends reinvested.
The funds that own Swedish Orphan Biovitrum
86 funds we follow own Swedish Orphan Biovitrum. The share is how much of the fund the stock makes up.
- Norway3
- Sweden82
- Denmark1
- 2 ETFs
- Öhman Sverige Hållbar ASweden · Öhman5.7%
- PLUS Hälsovård Sverige IndexSweden · PLUS5.0%
- Nordic Equities SwedenSweden4.8%
- Humle SverigefondSweden · Humle4.6%
- Nordic Equities StrategySweden4.3%
- HealthInvest Small & MicroCap Fund CSweden · HealthInvest4.2%
- HealthInvest Small & Mid Cap Healthcare ESweden · HealthInvest4.2%
- Aktie-Ansvar Sverige ASweden · Aktie-Ansvar4.0%
Show all 86
- CF Tillväxt Sverige ASweden · CF Tillväxt3.8%
- Lannebo Sverige PlusSweden · Lannebo3.7%
- Lannebo SverigeSweden · Lannebo3.7%
- AMF Aktiefond SverigeSweden · AMF3.1%
- PriorNilsson Sverige Aktiv ASweden · PriorNilsson3.1%
- Lannebo Hälsa och Ny Teknik ASweden · Lannebo3.0%
- Lärarfond 21-44 årSweden · Lärarfond2.8%
- Simplicity NordenSweden · Simplicity2.8%
- Nordea OlympiafondSweden · Nordea2.7%
- Nordea AlfaSweden · Nordea2.6%
- Simplicity Småbolag Sverige ASweden · Simplicity2.5%
- Simplicity SverigeSweden · Simplicity2.4%
- Alfred Berg Sverige Gambak R (SEK)Sweden · Alfred Berg2.4%
- Lysa Sverige Aktier BSweden · Lysa2.2%
- Lärarfond 45-58 årSweden · Lärarfond2.2%
- Öhman Småbolagsfond ASweden · Öhman2.0%
- XACT Sverige (UCITS ETF)Sweden · XACT · ETF1.7%
- Avanza Sweden All Cap ASweden · Avanza1.7%
- Öhman Sweden Micro Cap ASweden · Öhman1.6%
- Folksam LO SverigeSweden · Folksam1.6%
- Swedbank Robur Access Edge Sweden ASweden · Swedbank Robur1.5%
- AMF Aktiefond VärldenSweden · AMF1.4%
- Indecap Guide 2 BSweden · Indecap1.4%
- Skandia Sverige ExponeringSweden · Skandia1.4%
- Öhman Etisk Index Sverige ASweden · Öhman1.3%
- PLUS Allabolag Sverige IndexSweden · PLUS1.3%
- Swedbank Robur Sverige Selektiv ASweden · Swedbank Robur1.2%
- Carnegie Sverigefond ASweden · Carnegie1.1%
- Lärarfond 59+Sweden · Lärarfond1.1%
- IKC Sverige FlexibelSweden · IKC1.1%
- Nordea Inst Aktie SverigeSweden · Nordea1.1%
- SPP Aktiefond Sverige ASweden · SPP1.1%
- Öhman Sverige Marknad Hållbar ASweden · Öhman1.1%
- Nordnet Indexfond SverigeSweden · Nordnet1.1%
- Swedbank Robur Access Sverige ASweden · Swedbank Robur1.1%
- Länsförsäkringar Småbolag Sverige ASweden · Länsförsäkringar1.0%
- Levler MSCI Nordic by Xtrackers UCITS ETFSweden · Levler · ETF0.9%
- Alfred Berg Nordic Index R (SEK)Norway · Alfred Berg0.9%
- DNB Norden Indeks ANorway · DNB0.9%
- KLP AksjeNorden IndeksNorway · KLP0.8%
- Skandia NordenSweden · Skandia0.7%
- Skandia Världen SverigeSweden · Skandia0.7%
- Handelsbanken Norden Ind Crit (A1 NOK)Sweden · Handelsbanken0.7%
- Handelsbanken Hälsovård Tema (A1 SEK)Sweden · Handelsbanken0.6%
- GodFond Sverige & VärldenSweden · GodFond0.4%
- Handelsbanken Europa Ind Crit (A1 NOK)Sweden · Handelsbanken0.3%
- Handelsbanken Europa Index Crit (A1 SEK)Sweden · Handelsbanken0.3%
- Nordea Donationsmedelsfond utdSweden · Nordea0.2%
- Skandia SMART FörsiktigSweden · Skandia0.1%
- SPP Global Multifactor Plus ASweden · SPP0.1%
- Avanza EuropaSweden · Avanza0.1%
- Länsförsäkringar Sparmål 2025Sweden · Länsförsäkringar0.1%
- Länsförsäkringar Sparmål 2030Sweden · Länsförsäkringar0.1%
- Nordea Avtalspensionsfond MidiSweden · Nordea0.1%
- Wealth Invest SGA Globale AktDenmark · Wealth Invest0.1%
- SEB Europe Exposure B (SEK)Sweden · SEB0.1%
- Skandia Europa ExponeringSweden · Skandia0.1%
- Länsförsäkringar Europa IndexnäraSweden · Länsförsäkringar0.1%
- Öhman Etisk Index EuropaSweden · Öhman0.1%
- Lysa Global Aktier Hållbar BSweden · Lysa0.1%
- Handelsbanken Developed Markets Index Criteria (A1 SEK)Sweden · Handelsbanken0.1%
- Länsförsäkringar Global KlimatIndexSweden · Länsförsäkringar0.1%
- Handelsbanken Global Index Crit (A1 NOK)Sweden · Handelsbanken0.0%
- Nordea Stratega 70Sweden · Nordea0.0%
- SEB Active 80 ASweden · SEB0.0%
- Nordea Stratega 30Sweden · Nordea0.0%
- Nordea Stratega 50Sweden · Nordea0.0%
- SEB Active 55 ASweden · SEB0.0%
- AP7 AktiefondSweden · AP70.0%
- Avanza GlobalSweden · Avanza0.0%
- Handelsbanken Global Index Core (A1 SEK)Sweden · Handelsbanken0.0%
- Lysa Aktier CSweden · Lysa0.0%
- Länsförsäkringar Global IndexnäraSweden · Länsförsäkringar0.0%
- Nordea Stratega 10Sweden · Nordea0.0%
- PLUS Global IndexSweden · PLUS0.0%
- SEB Active 20 ASweden · SEB0.0%
- SEB Active 30 ASweden · SEB0.0%
- Öhman Global Marknad Hållbar ASweden · Öhman0.0%
From the funds' latest known holdings.
About Swedish Orphan Biovitrum
Swedish Orphan Biovitrum AB (publ) is a company in healthcare, listed on Nasdaq Stockholm. By market value, Swedish Orphan Biovitrum is number 2 of 137 companies in healthcare on Nasdaq Stockholm. Swedish Orphan Biovitrum has not paid a dividend in the past twelve months. Of the three measures in the ranking, Swedish Orphan Biovitrum is strongest on quality, better than 79% of Nordic stocks. The next report from Swedish Orphan Biovitrum is expected on 4 February 2027. The share trades in SEK. It has around 2,200 employees.
Swedish Orphan Biovitrum AB (publ), a biopharma company, provides medicines in the areas of haematology, immunology, and specialty care in Europe, North America, the Middle East, Asia, and Australia. The company operates through three segments: Haematology, Immunology, and Specialty Care. It offers Alprolix for haemophilia B; ALTUVOCT for the treatment and prophylaxis of bleeding in patients with haemophilia A; Aspaveli/Empaveli for treating adult patients with paroxysmal nocturnal haemoglobinuria; Doptelet for the treatment of immune thrombocytopenia and thrombocytopenia; Elocta/Eloctate for the treatment and prophylaxis of bleeding in patients with haemophilia A; Gamifant for treating hemo…


See the full analysis of Swedish Orphan Biovitrum.
The accounts, dividends, 40 years of charts and the comparison with other stocks are in the app.
Free forever · No card